TABLE 1.

Desmoplastic infantile astrocytoma/ganglioglioma cases

Patient, age, gender	Location, diagnosis, extent of resection	BRAF VE1	BRAF mutation	Clinical follow-up, length of survival (in months)
1, 3 months, F	R parietooccipital region DIA NTR	NEG	Failed Sanger, next-generation sequencing, qPCR mutational analyses	Alive with no recurrence 9 months
2, 1 month, M	R frontal lobe DIA STR	NEG	Failed Sanger, next-generation sequencing, qPCR mutational analyses	Treated at time of diagnosis with carboplatin/etoposide Alive with no recurrence 93 months
3, 11 months, F	R parietooccipital region DIA CR	NEG	Failed Sanger, next-generation sequencing, qPCR mutational analyses	Progressive leptomeningeal spread noted 2 months postoperatively. Therapy with high-dose chemotherapy, then temozolomide. Alive with no additional recurrence 195 months
4, 7 months, M	L cerebral hemisphere DIG CR	NEG	Mutation not identified on next-generation sequencing	Alive with no recurrence 8 months
5, 3 months, M	L temporal lobe DIG CR	NEG	Failed Sanger, next-generation sequencing, qPCR mutational analyses	Alive with no recurrence 36 months
6, 1 year, M	L cerebral hemisphere DIG CR	Equivocal Immunostaining	Mutation present (c.1799_1800TG>AT;V600D)	Alive with no recurrence 9 months

CR, complete resection; DIA, desmoplastic infantile astrocytoma; DIG, desmoplastic infantile ganglioglioma; F, female; L, left; M, male; NEG, negative; NTR, near total resection; POS, positive for mutation; qPCR, quantitative PCR. R, right; STR, subtotal resection;